Jose Donato Magno

Echo Enthusiast. Clinical Professor of Med & Cardiology. ASEANEcho Chair, @AUFcardio Exec Director, TheHeartSpecialists CEO. Tweets on

[Jose Donato Magno @doc_jdam]

“MALASAKIT”
The beauty of the 🇵🇭 Filipino language — capturing in one word the concept of having what I call ‘deep and authentic concern for another living being.’

[Jose Donato Magno @doc_jdam]

#TheHeartSpeaks 🎙️
𝗘𝗽𝗶𝘀𝗼𝗱𝗲 2: “Natatagong Panganib” - Hidden Danger
Understanding 𝗟𝗽(𝗮) — the inherited cholesterol risk that many people never know they have.

L - let’s
P - pause &
A - assess

▶️ https://t.co/yv2KBo9hGh…
“When the heart speaks, we listen.”

[Jose Donato Magno @doc_jdam]

𝗧𝗵𝗲 𝗛𝗲𝗮𝗿𝘁 𝗦𝗽𝗲𝗮𝗸𝘀
𝗧𝗵𝗲 𝗳𝗶𝗿𝘀𝘁-𝗲𝘃𝗲𝗿 𝗽𝗼𝗱𝗰𝗮𝘀𝘁 𝗼𝗳 𝗧𝗵𝗲 𝗛𝗲𝗮𝗿𝘁 𝗦𝗽𝗲𝗰𝗶𝗮𝗹𝗶𝘀𝘁𝘀 𝗖𝗹𝗶𝗻𝗶𝗰 𝗮𝗻𝗱 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰 𝗖𝗲𝗻𝘁𝗲𝗿

“When the heart speaks, we listen.”
#TheHeartSpeaks #TheHeartSpecialists

[Jose Donato Magno @doc_jdam]

#TheHeartSpeaks 🎙️
𝗘𝗽𝗶𝘀𝗼𝗱𝗲 𝟭: 𝗣𝗮𝗺𝗮𝗺𝗮𝗴𝗮 𝗻𝗴 𝗣𝘂𝘀𝗼
Understanding 𝗛𝘀-𝗖𝗥𝗣 - & why silent inflammation may be your heart’s hidden threat

C - check your
R - risk
P - promptly

▶️ https://t.co/dMIshCCa11
“When the heart speaks, we listen.”

[Jose Donato Magno @doc_jdam]

THE INNOVATION MINDSET

Everytime you encounter “impossible,” flip the switch and say “I’m possible.” 😎

[Jose Donato Magno @doc_jdam]

BRAUNWALD: Benchmark, Bible, and Byword

Many have shaped the world of CV medicine, but the passing of this big B admittedly hits differently especially among those who imbibed, breathed, regurgitated and dreamt of this household name during training years.

🙏@BraunwaldEugene

[American Heart Association @American_Heart]

The American Heart Association mourns the passing of the legendary cardiologist Eugene Braunwald, M.D., widely recognized as one of the most influential figures in the history of cardiovascular medicine. Over seven decades, his work reshaped the understanding and treatment of heart disease, leading many to call him the father of modern cardiology.

Braunwald was a lifelong contributor to the American Heart Association, helping advance its research and scientific mission, and was honored with some of the Association’s highest honors for his lasting influence on cardiovascular care and research. His influence extended well beyond his own discoveries, as generations of Association‑supported investigators, clinicians and academic leaders were trained by Braunwald or guided by the clinical trial standards and mentorship models he helped establish.

https://t.co/ieZuHYMyOP

[Jose Donato Magno @doc_jdam]

LDL: the “Lechon De Leche” of Lipidology

Lechon de leche refers to a popular and highly atherogenic 🇵🇭 dish with the roasted and milk-fed suckling pig prepared to crispy perfection. I use this analogy to remind patients re “big bad”cholesterol.

#BlockbusterBiomarkers

[Pablo Corral MD @drpablocorral]

👉Biomarkers for Cardiovascular
Drug Development
👉JACC State-of-the-Art Review

1️⃣ Not all biomarkers are created equal. LDL-C is.
It sits directly on the causal pathway of atherosclerosis—not adjacent, not associative, but causal.

2️⃣ Mechanism matters. LDL-C is “on-pathway.”
If you don’t lower LDL-C, you don’t meaningfully alter atherosclerotic biology.

3️⃣ Exposure–response is clean and monotonic.
Lower LDL-C → lower risk. No paradoxes, no U-shapes.

4️⃣ Consistency across therapies is unmatched.
Statins, ezetimibe, PCSK9 inhibitors, inclisiran, now oral PCSK9 inhibition—different mechanisms, same direction: ↓LDL-C → ↓events.

5️⃣ Trial-level validation? ✅
Individual-level validation? ✅
Decades of RCTs confirm that LDL-C reduction predicts and delivers cardiovascular benefit.

☝️Regulatory gold standard.
LDL-C is one of the very few biomarkers accepted as a validated surrogate endpoint for cardiovascular outcomes .
•Contrast that with the usual suspects:
•hs-CRP → inconsistent
•NT-proBNP → useful, not universal
•HDL-C → biologically appealing, clinically disappointing
•Triglycerides → context-dependent
•Lp(a) → promising, still awaiting definitive outcome linkage

☝️Key distinction:
Most biomarkers predict risk.
LDL-C modifies risk.
•Clinical implication:
If your strategy doesn’t aggressively reduce cumulative LDL-C exposure, you’re managing numbers—not disease.

📍Bottom line:
LDL-C is not just another biomarker.
It’s the central operational variable of atherosclerosis—the closest thing cardiology has to a “dose of disease.”

🔓Open access
🔗 https://t.co/VSWQagb7w6

@JACCJournals
@ACCinTouch
@society_eas
@nationallipid

[Jose Donato Magno @doc_jdam]

Uncertainty is the inescapable partner of ingenuity. ❔💡

[Jose Donato Magno @doc_jdam]

@apsc_office Gladly representing @PhilHeartAssoc and 🇵🇭 during this @apsc_office webinar to generate greater awareness regarding the “bangungut” myth now recognized as a genetically-linked condition known as Brugada syndrome and highlight our colleague’s advocacy. @GervacioGiselle

[Asian Pacific Society of Cardiology @apsc_office]

📣 APSC Cloud Forum
AI in Prevention & Precision Therapy of Cardiovascular Disease: Now & the Future
📅 Mar 25, 2026
⏰ 11:00–15:10 (Asia time zones)
https://t.co/MadO19HZEv

#APSC #Cardiology

[American College of Cardiology @ACCinTouch]

🆕 ACC/AHA Guideline on the Management of Dyslipidemia offers a comprehensive “one-stop shop” for addressing the evaluation, management & monitoring of individuals w/ dyslipidemias.

Read the full guideline in #JACC: https://t.co/rhUKNIRRL4 #cvLipids #ClinicalGuidelines

[Nadeen N. Faza, M.D. @NadeenFaza]

#ASEchoJC 🚨: Join us this Wed at 8 PM ET for a deep dive into the 2025 @ASE360 Guidelines Update for the Evaluation of LV Diastolic Function by #EchoFirst. 🫀

Diastology can be tricky… but we are here to decode & simplify it together with the expert guideline authors ✒️ and moderators: @SNagueh @dysanborn @BonitaEcho @PWesslyMD @HeartToProve

"See you" on Wednesday!
#Cardiotwitter #CardioX #Diastology #ACCFIT

[Jose Donato Magno @doc_jdam]

AGE is not just a state of MIND but a state of HEART.❤️

[JACC Journals @JACCJournals]

2026 ACC/AHA/Multisociety #ClinicalGuideline on acute pulmonary embolism highlights practice-changing recommendations for the evaluation & management of acute PE in adults.

Explore the Guideline-at-a-Glance in #JACC to accelerate adoption in practice: https://t.co/C10DhmN1gl

[Jose Donato Magno @doc_jdam]

Recognition of pathology is hinged heavily on mastery of normality.

[Jose Donato Magno @doc_jdam]

When in DOUBT, DON’T.

It’s always a good idea to pause during times of uncertainty. That momentary period for reflection can spell the difference between triumph or catastrophe.

[Jose Donato Magno @doc_jdam]

HURDLING THE HILL

Congratulations for staying the course. Before you know it, the initial toil and ordeal will be overcome by the view up there. And it can be breathtaking. ☀️🌄

[Thor Edvardsen @ThorEdvardsen]

This Consensus Paper #eacvi #ase is a great resource for anyone utilizing strain echocardiography in their clinical practice. Heart failure, cardio-oncology, valvaular disease, pulmonary hypertension, congenital heart disease

https://t.co/och9NvL9uw

[Jose Donato Magno @doc_jdam]

PATIENT CARE TAKES PATIENCE

When you lose PATIENCE, you lose PATIENTS.